Survival win has Bristol-Myers' Opdivo-Yervoy combo looking better as first-line kidney cancer treatment

7th September 2017 Uncategorised 0

The outlook brightened today for Bristol-Myers Squibb’s Opdivo as combo med as the drugmaker released more results from a test of its Opdivo-plus-Yervoy combination as a first-line treatment in kidney cancer. The overall survival results were promising enough that BMS stopped the trial early.

More: Survival win has Bristol-Myers' Opdivo-Yervoy combo looking better as first-line kidney cancer treatment
Source: fierce